A new therapy with bortezomib, an oncologic medicinal product of the year 2004;Question d'actualité: Une nouvelle thérapie ciblée avec le bortézomib, médicament oncologique de l'année 2004

Annales Pharmaceutiques Francaises

Volumn 63, Issue 5, 2005, Pages 343-349

  Monneret, Cl ^a   Buisson, J P ^a   Magdelenat, H ^a  

^a INSTITUT CURIE   (France)

Author keywords

Multiple myeloma; p53; Proteasome; Protein degradation; Ubiquitin

Indexed keywords

3 (4 AMINO 1,3 DIHYDRO 1,3 DIOXO 2H ISOINDOL 2 YL)GLUTARIMIDE; ANTINEOPLASTIC AGENT; BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; BORONIC ACID DERIVATIVE; BORTEZOMIB; DEXAMETHASONE; DIHYDROEPONEMYCIN; DOXORUBICIN; EPOXOMICIN; GELDANAMYCIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LACTACYSTIN; LACTACYSTIN BETA LACTONE; LENALIDOMIDE; MELPHALAN; MG 262; N SEC BUTYL 1 (2 CHLOROPHENYL) N METHYL 3 ISOQUINOLINECARBOXAMIDE; PROTAC 3; PROTEASOME; PROTEASOME INHIBITOR; PROTEIN P21; PROTEIN P27; PROTEIN P53; THALIDOMIDE; UBIQUITIN; UNCLASSIFIED DRUG; VINCRISTINE; PYRAZINE DERIVATIVE;

CANCER THERAPY; CONFERENCE PAPER; DIARRHEA; DRUG APPROVAL; DRUG INDICATION; DRUG MECHANISM; DRUG STRUCTURE; EUROPE; FATIGUE; HUMAN; MULTIPLE MYELOMA; NAUSEA; PERIPHERAL NEUROPATHY; PROTEIN DEGRADATION; THROMBOCYTOPENIA; TUMOR SUPPRESSOR GENE; UNITED STATES; VOMITING; ANIMAL; GENETICS; METABOLISM; NEOPLASM; PHYSIOLOGY; REVIEW;

ANIMALS; ANTINEOPLASTIC AGENTS; BORONIC ACIDS; HUMANS; MULTIPLE MYELOMA; NEOPLASMS; PROTEASOME ENDOPEPTIDASE COMPLEX; PYRAZINES; TUMOR SUPPRESSOR PROTEIN P53; UBIQUITIN;

EID: 26844452907     PISSN: 00034509     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0003-4509(05)82301-6     Document Type: Conference Paper

References (35)

1. Hershko A. Lessons from the discovery of the ubiquitin system. Trends Biochem Sci 1996; 21: 445-9.
2. Etlinger JD, Goldberg AL. A soluble ATP-dependent proteolytic system responsible for the degradation of abnormal proteins in reticulocytes. Proc Natl Acad Sci 1977; 74: 54-8.
3. Ciechanover A. The ubiquitin-proteasome proteolytic pathway. Cell 1994; 79: 13-21.
4. Kisselev AF, Goldberg AL. Review. Proteasome inhibitors: from research tools to drug candidates. Chem & Biol 2001; 8: 739-58.
5. Adams J. Potential for proteasome inhibition in the treatment of cancer. Drug Discov Today 2003; 8: 307-15.
6. Rock KL, Gramm C, Rothstein L, Clark K, Stein R, Dick L, et al. Inhibitors of the proteasome block the degradation of most cell proteins and the generation of peptides presented on MHC class I molecules. Cell 1994; 78: 761-71.
7. Omura S, Matsuzaki K, Fujimoto T, Kosuge K, Furuya T, Fujita S et al. Structure of lactacystin, a new microbial metabolite which induces differentiation of neuroblastoma cells. J Antibiot 1991; 44: 117-8.
8. Fenteany G, Standaert RF, Lane WS, Choi S, Corey EJ, Schreiber SL. Inhibition of proteasome activities and subunit-specific amino-terminal threonine modification by lactacystin. Science 1995; 268: 726-31.
9. Dick L, Cruikshank AA, Grenier L, Melandri FD, Nunes SL, Stein RL. Mechanistic studies on the inactivation of the proteasome by lactacystin. J Biol Chem 1996; 277: 7273-6.
10. Meng L, Kwok BH, Sin N, Crews CM. Eponemycin exerts its antitumor effect through the inhibition of proteasome function. Cancer Res 1999; 59: 2798-2801.
11. Groll M, Koguchi Y, Huber R, Kohno J. Crystal structure of the 20S proteasome: TMC-95A complex: a non-covalent proteasome inhibitor. J Mol Biol 2001; 311: 543-8.
12. Löwe J, Stock D, Jap B, Zwickl P, Baumeister W, Huber R. Crystal structure of the 20S proteasome from the Archaeon T. acidophilum at 3.4 Å resolution. Science 1995; 268: 533-9.
13. Adams J, Palombella VJ, Sausville EA, Johnson J, Destree A, Lazarus DD, et al. Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer Res 1999; 59: 2615-22.
14. Adams J, Behnke M, Chen S, Cruickshank AA, Dick LR, Grenier L, et al. Potent and selective inhibitors of the proteasome: dipeptidyl boronic acids. Bioorg Med Chem Letters 1998; 8: 333-8.
15. Bross PF, Kane R, Farrell AT, Abraham S, Benson K, Brower ME, et al. Approval summary for bortezomib for injection in the treatment of multiple myeloma. Clin Cancer Res 2004; 10: 3954-64.
16. Richardson P, Sonneveld P, Schuster MW, Irwin D, Stadtmauer EA, Facon T, et al. Bortezomib vs dexamethasone in relapsed multiple myeloma; A phase 3 randomized study. J Clin Oncology 2004; 22 (Suppl. 14): 6511; 40th ASCO, New Orleans, June 2004.
17. Lara PN, Davies AM, Mack PC, Mortenson MM, Bold RJ, Gumerlock PH et al. Proteasome inhibition with PS-341 (bortezomib) in lung cancer therapy. Semin Oncol 2004; 31 (1 Suppl 1): 40-6.
18. Papandreou CN, Logothetis CJ. Bortezomib as a potential treatment for prostate cancer. Cancer Res 2004; 64: 5036-43.
19. Papandreou CN, Daliani DD, Nix D, Yang H, Madden T, Wang X, et al. Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer. J Clin Oncol 2004; 22: 2108-21.
20. Ma MH, Yang HH, Parker K, Manyak S, Friedman JM, Altamirano C, et al. The proteasome inhibitor PS-341 markedly enhances sensitivity of multiple myeloma tumor cells to chemotherapeutic agents. Clin Cancer Res 2003; 9: 1136-44.
21. Mitsiades N, Mitsiades CS, Richardson PG, Poulaki V, Tai YT, Chauhan D, et al. The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications. Blood 2003; 101: 2377-80.
22. Cusack JC Jr, Liu R, Houston M, Abendroth K, Elliott PJ, Adams J., et al. Enhanced chemosensitivity to CPT-11 with proteasome inhibitor PS-341: implications for systemic nuclear factor-kB inhibition. Cancer Res 2001; 61: 3535-40.
23. Russo SM, Tepper JE, Baldwin AS Jr, Liu R, Adams J, Elliott P, et al. Enhancement of radiosensitivity by proteasome inhibition: implications for a role of NF-kappa B. Int J Radiat Oncol Biol Phys 2001; 50: 183-93.
24. Hideshima TP, Richardson P, Chauhan D, Palombella VJ, Elliott PJ, Adams J, et al. The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res 2001; 61: 3071-6.
25. Chauhan D, Li G, Podar K, Hideshima T, Mitsiades C, Schlossman R, et al. Targeting mitochondria to overcome conventional and bortezomib/proteasome inhibitor PS-341 resistance in multiple myeloma (MM) cells. Blood 2004; 104: 2458-66.
26. Cavenagh JD, Oakervee H. Thalidomide in multiple myeloma: current status and future prospects. Brit J Haematology 2003; 120: 18-26.
27. Theo SK, Stirling DI, Zeldis JB. Thalidomide as a novel therapeutic agent: new uses for an old product. Drug Discovery Today 2005; 10: 107-14.
28. Monneret C. Histone deacetylase inhibitors. Eur J Med Chem 2005; 40: 1-13.
29. Catley L, Weisberg E, Tai Y-T, Atadja P, Remiszewski S, Hideshima T, et al. NVP-LAQ824 is a potent novel histone deacetylase inhibitor with significant activity against multiple myeloma. Blood 2003; 102: 2615-22.
30. Tarte K, Klein B. Le myélome multiple: un nouveau cancer induit par un virus? médecine/sciences 1998; 14: 736-41.
31. Orlowski R, Small G, Shi Y. Proteasome inhibition activates a p38 MAPK-dependent anti-apoptotic program involving MKP-1 and Akt. Eur J Cancer 2004; 2 suppl.: abstract 43 p. 17.
32. Anderson KC. Targeting the myeloma cell in its bone marrow microenvironment. Eur J Cancer 2004; 2 suppl.: abstract 241 p. 75.
33. Verma R, Peters NR, D'Onofrio M, Tochtrop GP, Sakamoto KM, Varadan R, et al. Ubistatins inhibit proteasome-dependent degradation by binding the ubiquitin chain. Sciences 2004; 306: 117-20.
34. Sakamoto KM, Kim RB, Kumagai A, Mercuric F, Crews CM, Deshaies RJ. Protacs: chimeric molecules that target proteins to the SKp1-Cullin-F box complex for ubiquitination and degradation. Proc Natl Acad Sci USA 2001; 98: 8554-9.
35. Schneekloth JS Jr, Fonseca FN, Koldobskiy M, Mandal A, Deshaies R, Sakamoto K, et al. Chemical genetic control of protein levels: selective in vivo targeted degradation. J Am Chem Soc 2004; 126: 3748-54.